Each dose increase brings a renewed wave of appetite suppression
This leaves a wet cake behind for subsequent process steps
However: Larger meta-analyses show no significant increase in risk after adjusting for confounders [25] Incidence appears similar to other diabetes therapies [25] Much of the observed signal likely reflects: Baseline risk (obesity, T2DM) Secondary gallstone disease In summary, pancreatitis in GLP-1 users is a rare and possible complication, but current evidence does not support a substantial increase in risk directly related to GLP-1 agents
But the base still grows when more people start than stop, and that is what is happening: each quarter there are more current users than the one before
Prior Authorization, Step Therapy, Quantity Limits, and Annual or Lifetime Caps Insurance carriers often impose strict utilization management requirements before approving coverage, including prior authorization, step therapy, quantity limits, and annual or lifetime caps on benefits
Efficacy and safety of tirzepatide, dual GLP-1/GIP receptor agonists, in the management of type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials
